Fig. 7: CLL1CART with TRAC-KO is effective against the HM2130 PDX model.
From: Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia
A Schematic of the murine trial design with injection of 5e6 CAR or UTD T cells. B Flow cytometric assessment of JMML burden in PB over time. p-values d33/d46: CLL-1 KO vs. UTD KO = 0.0087/0.0451, CLL-1 KO vs. PBS = ****/0.0005, UTD KO vs. PBS = 0.0050/0.0394; ****<0.0001. C Flow cytometric assessment of leukemia burden in different tissues upon termination 47 days after (CAR) T cell injection. p-values CLL-1 KO vs. UTD KO BM [%]/BM [e6]/spleen [%]/cardiac blood = 0.0293/ 0.0323/0.0204/0.0008; CLL-1 KO vs. PBS BM [%]/BM [e6]/spleen [%]/cardiac blood = 0.0055/0.0087/0.0006/0.0085. D Flow cytometric assessment of LSC amount by staining for CD34 in different tissues upon termination. p-values CLL-1 KO vs. UTD KO BM/spleen/cardiac blood = 0.0055/0.0009/0.0009. E, F Flow cytometric analysis subsetting cells from (D) into CD34+CD38− (E) and CD34+CD38+ cells (F). p-values (E) CLL-1 KO vs. UTD KO spleen/cardiac blood = 0.0271/0.0039, CLL-1 KO vs. PBS BM/spleen/cardiac blood = 0.0016/****/0.0010; p-values (F) CLL-1 KO vs. UTD KO BM/spleen/cardiac blood = 0.0033/0.0011/0.0008; ****<0.0001. G Schematic of murine trial design with injection of 1e6 and later 10e6 CAR or UTD T cells. n = 7 mice for CLL-1 KO and UTD KO, n = 3 for PBS. H Flow cytometric assessment of JMML burden for the same study as in (G) in PB over time. I Survival curve for the study in (G). Statistical analysis was performed by the Log-rank (Mantel–Cox) test. p-values: CLL-1 KO vs. UTD KO = 0.0161, CLL-1 KO vs. PBS = 0.0027. n = 7 mice for CLL-1 KO and UTD KO, n = 4 for PBS. Statistical analysis for (B–F) was performed by one-way ANOVA with Tukey’s multiple comparisons test.
